SCHEMBL6984878

SCHEMBL6984878

NC1=COOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11954073 0.50
SCHEMBL14158450 0.50
SCHEMBL320324 0.50
SCHEMBL515670 0.45
SCHEMBL18649660 0.45
SCHEMBL248228 0.44
SCHEMBL108867 0.35
SCHEMBL63148 0.35
SCHEMBL320609 0.35 MEN1 (1.00)
SCHEMBL3387 0.35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103237801-B Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells HANMI HOLDINGS Co.,Ltd. (KR) 2015-11-25 CN claimed
CN-103237801-A Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells HANMI HOLDINGS CO LTD 2013-08-07 CN claimed
EP-4408843-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY Viva Star Biosciences (Suzhou) Co., Ltd. (CN) 2024-08-07 EP disclosed
US-20240246908-A1 TEAD INHIBITORS ORION CORPORATION (FI) 2024-07-25 US disclosed
WO-2024125626-A1 NITROGENOUS COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) 2024-06-20 WO disclosed
EP-4384510-A1 COMPOUNDS TARGETING MUTANT OF P53 Jacobio Pharmaceuticals Co., Ltd. (CN) 2024-06-19 EP disclosed
CN-111825701-B Tricyclic FXR modulator compounds containing benzothiazole 正大天晴药业集团股份有限公司 2023-12-08 CN disclosed
EP-4217348-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BeiGene, Ltd. (KY) 2023-08-02 EP disclosed
WO-2023125530-A1 ANTIBODY DRUG CONJUGATES BEIGENE, LTD. (KY) 2023-07-06 WO disclosed
WO-2023056264-A1 NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2023-04-06 WO disclosed
CN-112585128-B Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2023-02-21 CN disclosed
CN-103122001-A Polo-like kinase inhibitors TAKEDA PHARMACEUTICAL 2013-05-29 CN disclosed
WO-2012158099-A1 A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS ASTRAZENECA AB (SE) 2012-11-22 WO disclosed
CN-102149716-A Process for the preparation of [1S-[1α,2α,3β (1S*, 2R*), 5β]]-3-[7-[2-(3, 4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2, 3-triazolo [4,5-d] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1, 2-diol and intermediates thereof ASTRAZENECA AB 2011-08-10 CN disclosed
CN-101917995-A POLO-like kinase inhibitors TAKEDA PHARMACEUTICAL 2010-12-15 CN disclosed
CN-101687864-A 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors ASTRAZENECA AB 2010-03-31 CN disclosed
CN-101374818-A Pyrimidine derivatives ASTRAZENECA AB (SE) 2009-02-25 CN disclosed
CN-1478088-A Benzothiophene derivatives, process for their preparation and their use ά��ʵ�������޹�˾ 2004-02-25 CN disclosed
EP-1337528-A2 BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF LABORATORIOS VITA, S.A. (ES) 2003-08-27 EP disclosed
WO-2002044170-A2 BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF LABORATORIOS VITA, S.A. (ES) 2002-06-06 WO disclosed